Cancer Family
Cutaneous Melanocytic Neoplasm
CI-CAN-00000154Explore in graph →
Non-malignant81 active trials1 approved drugs61 evidence items
- NCIt
- C7161
Loading cancer entity…
Cancer Family
CI-CAN-00000154Explore in graph →
Clinical trials
254 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT06666790 | DermaSensor Postmarket Surveillance Study | recruiting | N/A | 396 | DermaSensor, Inc.INDUSTRY | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06602648 | MELCAYA - Novel Health Care Strategies for Melanoma in Children, Adolescents, and Young Adults - Work Package 3 (WP3)(Mol-Mel) | recruiting | — | 100 | University of FlorenceOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03842943 | Neoadjuvant Combination Immunotherapy for Stage III Melanoma | recruiting | Phase 2 | 28 | University of LouisvilleOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05446155 | BioMEL- Diagnostic and Prognostic Factors in Melanoma.(BioMEL) | recruiting | — | 2,000 | Region SkaneOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | recruiting | Phase 3 | 140 | Peking University Cancer Hospital & InstituteOTHER | 1 | Sep 6, 2023 | clinicaltrials |
| NCT05253872 | The MELAcare Study: A New Method for Surveillance of Melanoma Patients | recruiting | N/A | 378 | Herlev and Gentofte HospitalOTHER | 1 | Jun 26, 2023 | clinicaltrials |
| NCT04331093 | Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma | recruiting | Phase 2 | 40 | Di WuOTHER | 1 | May 26, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Nov 25, 2024source: clinicaltrials